FDA stamps OK on UroGen's chemo gel — putting Liz Barrett and team's commercial chops to test amid pandemic
A year and three months after Liz Barrett left Novartis’ oncology group to helm one of Arie Belldegrun’s lesser known biotech ventures, she is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
